Brainomix Extends U.S. Footprint With Systemwide WVU Health Deployment of AI Stroke Platform

New updates have been reported about Brainomix.

Brainomix has expanded its U.S. presence with the full deployment of its Brainomix 360 Stroke AI imaging platform across all 25 hospitals in the West Virginia University (WVU) Health System, giving the entire network a unified tool for acute stroke assessment and treatment decisions. The rollout positions Brainomix as the core imaging decision-support layer for WVU’s stroke services, standardizing interpretation across academic medical centers and community hospitals and potentially deepening the company’s commercial relationship with one of the region’s largest health systems.

Brainomix 360 Stroke is a fully automated platform that analyzes CT, CTA, CTP, and MRI scans in real time to provide objective insights throughout the stroke pathway, including whether patients should be transferred to specialist centers for advanced interventions. By reducing variability in image interpretation and integrating with existing telestroke workflows, the technology is intended to shorten time to treatment for high-risk cases such as large-vessel occlusions, which could translate into stronger clinical outcomes and strengthen Brainomix’s value proposition in future health system negotiations.

CEO and Co‑Founder Dr. Michalis Papadakis framed the WVU deployment as a model for how large, complex health systems can scale AI imaging to deliver consistent, expert-level stroke care, underscoring Brainomix’s strategy to embed its platform at network level rather than on a single‑site basis. WVU’s leadership highlighted the deal as a step toward equitable stroke care across urban and rural facilities, signaling that Brainomix’s technology is now central to the system’s patient care and IT strategy.

The agreement reinforces Brainomix’s positioning as a global pioneer in AI medical imaging for stroke and lung fibrosis and adds a high-visibility U.S. reference customer to its installed base, which already spans more than 20 countries. While financial terms were not disclosed, the systemwide implementation indicates recurring software revenue potential, supports future cross‑sell opportunities for Brainomix 360 e‑Lung, and strengthens the company’s competitive stance in the hospital AI imaging market, where scale, workflow integration, and demonstrated impact on outcomes are critical to long‑term adoption and enterprise-level contracts.